ArticleEuropean journal of breast health2025
Evaluation of Perforator Fasciocutaneous Flaps for Oncoplastic Immediate Reconstruction Following Breast Conservative Surgery in Lower and Lateral Breast Quadrant Lesions Perforator Fasciocutaneous Flaps for OBCS.
Article in European journal of breast health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Versatility of Lateral Intercostal Artery Perforator Flaps in Partial Breast Reconstruction: First National Experience of Peru.European journal of breast health · 2026Article
- The anterior intercostal artery perforator flap in immediate oncoplastic breast reconstruction: current applications and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the oncological safety and the cosmetic outcome of the techniques anterior intercostal artery perforator (AICAP), lateral intercostal artery perforator (LICAP) and thoracodorsal artery perforator (TDAP) flap as a volume replacement technique to eliminate deformity and preserve breast cosmesis by filling the excised defect. Materials and Methods: This prospective study included women with lower outer quadrant, lower inner quadrant, and upper outer quadrant tumors who underwent upfront or post-neoadjuvant chemotherapy breast conserving surgery with immediate volume replacement surgery. Patients were allocated into three groups at a ratio of 1:1: Group A ( Results: Regarding postoperative complications, wound infection took place in only one (10%) patient in LICAP group and one (10%) patient in the AICAP group; seroma occurred in only one (10%) patient in LICAP group and one (10%) patient in the TDAP group; and fat necrosis occurred in only one (10%) patient in the TDAP group. Incidence of wound infection, seroma, and fat necrosis was insignificantly different among the studied groups. Breast distortion occurred in one (10%) patient in the AICAP group and not observed in the other groups, and partial flap necrosis occurred in one (10%) patient in the LICAP group and one (10%) patient in the AICAP group and was not observed in the TDAP group. Incidence of distortion and partial flap necrosis were insignificantly different between the studied groups. The conservative treatment of breast cancer core results, surgeon's assessment, patient's satisfaction and breast Q scores did not differ between the three groups. Conclusion: A better cosmetic outcome than level II oncoplastic techniques, the perforator fasciocutaneous flaps, LICAP, AICAP, and TDAP, were effective and safe options for immediate breast reconstruction after breast-conserving surgery. All three techniques showed similar surgical outcomes, low complication rates, and good aesthetic results. Patient satisfaction was high, with no significant differences between the groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.